From myelofibrosis stem cell biology to measurable residual disease (MRD) risk stratification in acute myeloid leukemia (AML), Tapestri single-cell multiomics is at the center of the science being presented at the European Hematology Association Congress
SOUTH SAN FRANCISCO, CA, June 1, 2026. Mission Bio, the leader in single-cell multiomics, today announced that its Tapestri platform supported several research presentations, including three oral presentations, at the 2026 European Hematology Association (EHA) Congress, taking place June 11-14, 2026, in Stockholm, Sweden. The studies span a broad range of hematologic malignancies and pre-leukemic conditions, and across every disease, where collectively, the message is the same: bulk sequencing cannot resolve the clonal complexity that drives outcomes, and Tapestri can.
These studies, conducted by independent academic and industry research groups across Europe, Asia, and North America, demonstrate how single-cell DNA, protein, and now epigenomic profiling on the Tapestri platform is changing the way hematologists identify disease-propagating stem cells, predict relapse, monitor therapeutic response, and define new disease subtypes.
Integrated Single-Cell Profiling Identifies Relapse-Associated Clonal Dynamics and Refines Measurable Residual Disease (MRD) Risk Stratification in AML
Lead author: Enise Ceran
In a BLAST trial cohort, integrated Tapestri DNA-and-protein profiling produced an MRD pathogenicity score that predicted relapse-free survival, potentially redefining MRD from a single number into a clonal landscape resolvable at single-cell resolution.
Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, Produces Clonal Molecular Responses that Correlate with Clinical Responses in Patients with Myelofibrosis
Lead author: Jyoti Nangalia
In the Phase 1 program for INCA033989, Tapestri revealed substantial reductions of mutant CALR HSPCs in every clinical responder — depth of response that bulk NGS failed to capture and that will be central to how this drug class is developed.
CD9 Marks the Disease-Propagating Hematopoietic Stem Cell Population in Myelofibrosis
Lead author: Lara Tavernari
Tapestri single-cell mutational and surface protein profiling identified CD9 as a marker of the malignant stem cell compartment in myelofibrosis, nominating it as a therapeutic target to eradicate a clone that current JAK inhibitors fail to clear.
Resolving the Tumor Heterogeneity of CLL Subset #8 at Single-Cell Resolution: Insights into Clonal Dynamics and Distinct Sub-Clonal Mutational Landscapes
Lead author: Athanasios Roussos
Tapestri single-cell DNA sequencing tracked a minor subclone present at diagnosis as it expanded under sequential BTKi and BCL2 inhibitor pressure to dominate at Richter Transformation, demonstrating that the clones driving transformation are visible years before they emerge clinically.
Single-Cell Joint Profiling of Genotypes, Epigenome, and Transcriptomes in TET2-Mutant Clonal Pre-Leukemic Lesions
Lead author: Masanori Motomura
Tapestri enabled simultaneous single-cell ATAC-seq and genotyping in TET2-mutant clonal hematopoiesis, establishing the platform as the foundation for mechanistically dissecting the earliest stage of myeloid malignancy.
An Integrative Approach Combining Single-Cell DNA-Seq and Surfaceome Reveals Distinct Evolutionary Trajectories Specific to Somatic Abnormalities in GATA2 Deficiency
Lead author: Hedi Somai
Tapestri DNA sequencing with surface protein profiling resolved the clonal hierarchy in GATA2-deficient patients, distinguishing leukemogenic initiating events from progression drivers in a setting where transplantation timing decisions hinge on exactly that distinction.
Ectopic Activation of FOXF1 and FENDRR by t(14;16)(q32;q24) Identifies a High-Risk T-ALL/MPAL Subtype
Lead author: Danica Di Giacomo
Tapestri helped define a novel high-risk acute leukemia subtype driven by a recurrent t(14;16) translocation, demonstrating that new disease entities are still being discovered — and made actionable — through single-cell resolution.
The Pattern Across These Studies
Read together, these presentations demonstrate a shift in how hematology is being practiced and how hematologic drugs are being developed.
Bulk sequencing produces averages. Averages miss the disease-propagating clone, miss the resistant subclone hiding at remission, miss the early initiator that determines transplant timing, and miss the depth of response that determines whether a new mechanism is truly disease-modifying. Every one of the studies describes a question that could not be answered without resolving the hematological disease at the level of individual cells, often combining DNA with protein analysis, and now with epigenetic and targeted transcript data all in one assay.
“What you're seeing at EHA this year is a category of science maturing," said Zivjena Vucetic, MD, PhD, Chief Medical Officer of Mission Bio. “Tapestri is now the platform investigators reach for when the scientific question demands clonal resolution, identifying the disease-propagating stem cell, predicting relapse from residual disease, measuring true depth of molecular response, and resolving the clonal architecture that determines clinical decisions. The investigators presenting this work are the people who write the guidelines. Their adoption of single-cell multiomics signals where the field is going.”
Mission Bio is actively partnering with academic centers and biopharmaceutical sponsors to integrate Tapestri-based profiling into clinical trial design as a foundational stratification tool.
About Mission Bio
Mission Bio is the single-cell multi-omics leader. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional standard-of-care methods, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. With the Tapestri Platform, Mission Bio continues to set the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit missionbio.com.
Media Contact